Press release
Gossamer Bio Announces Data Presentations at the European Respiratory Society Congress 2024
- Additional Phase 2 TORREY Open-Label Extension Data to be Presented in Vienna - SAN DIEGO--(BUSINESS WIRE)-- Gossamer Bio, Inc. (Nasdaq: GOSS), a
About this update from Gossamer Bio, Inc.
[{"type":"text","content":"\n- Additional Phase 2 TORREY Open-Label Extension Data to be Presented in Vienna -\n\n\n SAN DIEGO--(BUSINESS WIRE)--\nGossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), today announced two oral presentations and a poster presentation with data relevant to seralutinib at the European Respiratory Society (ERS) Congress 2024, which takes place from September 7th through 11th online and onsite in Vienna, Austria.\n\n\n“We are thrilled to present additional findings from our Phase 2 TORREY open-label extension study at the European Respiratory Society Conference in Vienna which highlight the sustained effect of seralutinib beyond 24 weeks of treatment,” said Faheem Hasnain, Co-Founder, CEO, and Chairman of Gossamer Bio.\n\n\n“With the continued improvement in clinical outcome measures and the sustained effect on circulating biomarkers of proteins and pathways relevant to PAH pathogenesis, these data demonstrate the potential of seralutinib to make a meaningful difference in the lives of people living with pulmonary hypertension. These findings reinforce our commitment to advancing the development of seralutinib for the treatment of patients with PAH and PH-ILD,” added Mr. Hasnain.\n\n\nPresentations related to Seralutinib, an Inhaled PDGFR, CSF1R and c-KIT Inhibitor\n\n\nSession Type: Oral Presentation\nSession Title: Novel Aspects in Pulmonary Hypertension\nSession Date & Time: September 8th, 2:15pm – 3:30pm CEST\nPresentation Time: 2:25pm CEST\nLocation: Lehar 3\nAbstract Number: 1871\nPresentation Title: Sustained benefit with seralutinib treatment: a post-hoc analysis of the TORREY open-label extension\nPresenter: Dr. Vallerie V. McLaughlin\n\n\nSession Type: Oral Presentation\nSession Title: Novel Aspects in Pulmonary Hypertension\nSession Date & Time: September 8th, 2:15pm – 3:30pm CEST\nPresentation Time: 2:30pm CEST\nLocation: Lehar 3\nAbstract Number: 1872\nPresentation Title: Sustained effect of seralutinib on circulating biomarkers in the TORREY phase 2 open-label extension study\nPresenter: Prof. Hossein-Ardeschir Ghofrani\n\n\nSession Type: Poster Presentation\nSession Title: Novel aspects in p...